The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock
- PMID: 15868139
- DOI: 10.1007/s00134-005-2596-2
The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock
Abstract
Objective: Multiple-organ failure (MOF) is defined as the progressive deterioration in function which occurs in several organs or systems in patients with septic shock, multiple trauma, severe burns, or pancreatitis. This study investigated the effect of 15-deoxy-delta(12,14)-PGJ2 (15d-PGJ2), a PPAR-gamma ligand, in a model of zymosan-induced nonseptic shock in mice.
Materials and methods: Mice were randomly assigned to one of four groups (n=10 each) and treated i.p. as follows: group 1, zymosan (500 mg/kg suspended in saline solution) and vehicle (10% DMSO); group 2, zymosan (500 mg/kg suspended in saline solution) plus 15d-PGJ2 (30 microg/kg, suspended in 10% DMSO) 1 h before and 6 h after zymosan administration; group 3, 15d-PGJ2 (30 microg/kg, suspended in 10% DMSO; group 4, vehicle for PGJ2 (10% DMSO) always 1 h before and 6 h after saline administration. After 18 h mice were killed and tissues and biological fluids used for biochemical, immunohistochemical, and histological analysis.
Measurements and results: 15d-PGJ2 inhibited the inflammatory response and significantly reduced peritoneal mononuclear cell infiltration and histological injury in mice. A significant protection was demonstrated in kidney, liver, and pancreas injury by the reduction in amylase, lipase, creatinine, AST, ALT, bilirubin, and alkaline phosphatase levels. 15d-PGJ2 also reduced the appearance of nitrotyrosine in the inflamed intestinal tissues. Histological examination revealed a significant reduction in zymosan-induced intestinal damage in 15d-PGJ2 treated mice.
Conclusions: Our findings demonstrate that 15d-PGJ2 exerts potent anti-inflammatory effects on zymosan-induced shock.
Comment in
-
Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?Intensive Care Med. 2005 May;31(5):605-8. doi: 10.1007/s00134-005-2595-3. Epub 2005 Mar 22. Intensive Care Med. 2005. PMID: 15782317 No abstract available.
Similar articles
-
Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin.Crit Care Med. 2004 Mar;32(3):826-31. doi: 10.1097/01.ccm.0000114821.25573.e7. Crit Care Med. 2004. PMID: 15090969
-
The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock.Shock. 2004 Dec;22(6):555-61. doi: 10.1097/01.shk.0000144132.13900.24. Shock. 2004. PMID: 15545828
-
15d-prostaglandin J2 reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria.Eur J Pharmacol. 2004 Sep 13;498(1-3):295-301. doi: 10.1016/j.ejphar.2004.07.074. Eur J Pharmacol. 2004. PMID: 15364008
-
Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury.Shock. 2008 Aug;30(2):142-52. doi: 10.1097/SHK.0b013e31815dd381. Shock. 2008. PMID: 18628687
-
15d-PGJ2: the anti-inflammatory prostaglandin?Clin Immunol. 2005 Feb;114(2):100-9. doi: 10.1016/j.clim.2004.09.008. Clin Immunol. 2005. PMID: 15639643 Review.
Cited by
-
Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?Intensive Care Med. 2005 May;31(5):605-8. doi: 10.1007/s00134-005-2595-3. Epub 2005 Mar 22. Intensive Care Med. 2005. PMID: 15782317 No abstract available.
-
Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.Intensive Care Med. 2006 Apr;32(4):490-500. doi: 10.1007/s00134-006-0068-y. Epub 2006 Feb 18. Intensive Care Med. 2006. PMID: 16489423 Review. No abstract available.
-
Effects of 15-deoxy-Delta12,14-prostaglandin-J2 during hyperdynamic porcine endotoxemia.Intensive Care Med. 2006 May;32(5):759-65. doi: 10.1007/s00134-006-0107-8. Epub 2006 Mar 14. Intensive Care Med. 2006. PMID: 16534570
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources